China Pharma Holdings, Inc.
CPHI
$0.65
-$0.01-1.39%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.11% | -31.27% | 10.91% | -17.05% | -47.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.11% | -31.27% | 10.91% | -17.05% | -47.25% |
| Cost of Revenue | -16.95% | -49.63% | -42.65% | -23.35% | -41.91% |
| Gross Profit | 193.90% | 88.51% | 91.43% | 53.07% | -102.78% |
| SG&A Expenses | 12.18% | 10.50% | 156.94% | -0.27% | 8.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.11% | -36.68% | -34.07% | -17.10% | -30.12% |
| Operating Income | -0.31% | 42.16% | 63.97% | 17.19% | -0.97% |
| Income Before Tax | 0.19% | 41.72% | 63.26% | 17.82% | 0.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.19% | 41.72% | 63.26% | 17.82% | 0.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.19% | 41.72% | 63.26% | 17.82% | 0.63% |
| EBIT | -0.31% | 42.16% | 63.97% | 17.19% | -0.97% |
| EBITDA | 6.11% | 30.03% | 72.31% | -135.49% | -53.06% |
| EPS Basic | 65.93% | 73.96% | 81.84% | 66.42% | 68.65% |
| Normalized Basic EPS | 65.93% | 73.97% | 81.84% | 66.42% | 68.64% |
| EPS Diluted | 65.93% | 73.96% | 81.84% | 66.42% | 68.65% |
| Normalized Diluted EPS | 65.93% | 73.97% | 81.84% | 66.42% | 68.64% |
| Average Basic Shares Outstanding | 193.02% | 123.85% | 102.31% | 144.69% | 216.91% |
| Average Diluted Shares Outstanding | 193.02% | 123.85% | 102.31% | 144.69% | 216.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |